Loading...

Archive

    02 July 2017, Volume 33 Issue 7 Previous Issue    Next Issue

    For Selected: Toggle Thumbnails
    Perinatal anticoagulation management of pregnant women with cardial prosthetic valve replacement
    HUANG Tao-tao,LIN Jian-hua
    2017, 33(7): 667-671.  DOI: 10.19538/j.fk2017070102
    Abstract ( )  

    Pregnancy of women with cardial prosthetic valve replacement belongs to high-risk pregnancy.To ensure the safety of both mother and fetus,assessment of heart disease before pregnancy and multidisciplinary management during pregnancy should be done.At the same time,we should select appropriate anticoagulation therapy,monitor the condition closely and maintain the stability of coagulation state,and adjust the coagulation function in advance according to the comprehensive analysis of patients’ medical history,valvular status,anticoagulant dose and gestational weeks.

    Anticoagulation therapy for recurrent spontaneous abortion
    WU Shu-yan,ZHANG Jian-ping
    2017, 33(7): 671-675.  DOI: 10.19538/j.fk2017070103
    Abstract ( )  

    The physiological and pathological changes of blood coagulation state in some pregnant women with recurrent spontaneous abortion often lead to fetal loss.Proper application of low molecular weight heparin and aspirin and the other anticoagulant drugs can effectively improve the outcomes of these patients and play an important role in the treatment of these patients.

    Perinatal anticoagulation therapy for obstetric antiphospholipid syndrome
    HUANG Shu-hui,LIU Huai
    2017, 33(7): 675-678.  DOI: 10.19538/j.fk2017070104
    Abstract ( )  

    Antiphospholipid syndrome(APS)is classified as one associated with thrombosis and/or pathological pregnancy and being persistently positive for antiphospholipid antibodies.APS can increase pregnancy complications,such as recurrent pregnancy loss,premature birth,stillbirth,intrauterine death,preeclampsia,and fetal growth restriction.An association  is found between adverse pregnancy outcome and thrombophilias.Treatment for perinatal APS are mainly symptomatic treatment,preventing the recurrence of thrombosis and pathological pregnancy.The use of low-dose aspirin and heparin has improved the pregnancy outcome in obstetric antiphospholipid syndrome.

    Evaluation of the screening and anticoagulation therapy for inherited thrombophilias in pregnancy.
    LIAN Yan,WANG Xie-tong
    2017, 33(7): 678-684.  DOI: 10.19538/j.fk2017070105
    Abstract ( )  

    In Han populations,deficiencies in protein S and protein C are most common,and deficiencies in  antithrombin are not common,while FⅤL mutation and PGM mutation are rare.Inherited thrombophilias increase the risk of gestational venous thromboembolism,and become a contributory factor rather than a single cause of such placenta- mediated pregnancy complications.If there are clear indications for treatment,there is no need for any inherited thrombophilias screening.Screening may be useful if the cause is unknown and the positive outcome of inherited antithrombotic screening may affect treatment decisions.The existing evidence suggests that prophylactic use of low-dose aspirin can reduce pre-eclampsia.Regarding the question whether LMWH can reduce the risk of recurrence of placenta-mediated pregnancy complications,the conclusions of single center and multi-center studies are different.Despite limited evidence of efficacy,it is recommended to use selective and personalized anticoagulant therapy to prevent these complications.

    Anticoagulation therapy for pregnancy complicated with autoimmune diseases
    WANG Li-ping,ZHONG Mei
    2017, 33(7): 684-688.  DOI: 10.19538/j.fk2017070106
    Abstract ( )  

    The physiological and pathological changes of thrombophilia in pregnant women with autoimmune diseases often lead to severe pregnancy complications and adverse pregnancy outcomes.Low molecular weight heparin and aspirin,as the safe pregnancy medication,play an important role in improving the outcomes of these patients.Standardized treatment of anticoagulation helps to improve the maternal and fetal adverse outcomes.

    Related problems of aspirin in preventing preeclampsia
    CHEN Guo-qing, NIU Jian-min
    2017, 33(7): 688-691.  DOI: 10.19538/j.fk2017070107
    Abstract ( )  

    Preeclampsia is a common obstetric disease that seriously threatens maternal and fetal safety,so reducing its incidence is of great significance.Recent studies have shown that aspirin plays an important role in the prevention of preeclampsia by acting on the key targets of preeclampsia,such as cyclooxygenase 1 (COX1).To grasp the indications and timing of aspirin to prevent preeclampsia along with reasonable medication after excluding the contraindications can effectively reduce the incidence of preeclampsia,or slow down the severity of the disease.

    Team management and anticoagulation treatment for amniotic fluid embolism - the current viewpoint
    CHEN Dun-jin,CHEN Yan-hong
    2017, 33(7): 691-694.  DOI: 10.19538/j.fk2017070108
    Abstract ( )  

    Amniotic fluid embolism(AFE)is one of the catastrophic complications of pregnancy,and it is often life-threatening to pregnant women and fetus.Although the cause is clear,but the exact mechanisms of AFE are still unclear.The use of anticoagulant in AFE therapy remains controversial when disseminated intravascular coagulation(DIC)occurs.AFE is often with acute onset and develops rapidly,so it’s hard to select the best time to use anticoagulant,and improper use of anticoagulant may aggravate the disease.So,anticoagulant isn't recommended for routine use in clinics.Based on the treatment experience and lessons of AFE at home and abroad,early recognition and a rapid response team are the key to successful treatment of AFE.